Daniel D. Burgess
President and Chief Executive Officer

Mr. Burgess has 19 years experience in management, operational and financial roles in the biotechnology and pharmaceutical industries. Most recently, Mr. Burgess was the Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, Inc., a publicly traded biotechnology company focused on biodefense, infectious disease and immune system disorders. Prior to joining Hollis-Eden, Mr. Burgess was employed at Nanogen, Inc., a publicly traded biotechnology company developing microarray technology, where he served as Vice President and Chief Financial Officer. Previously, he spent ten years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Limited), a specialty pharmaceutical firm, where his positions included Vice President and Chief Financial Officer responsible for finance and business development and at Gensia Automedics, Inc., a medical products company, where he served as President and as a director. At Gensia he was heavily involved in numerous in-licensing and out-licensing transactions with a number of large pharmaceutical companies and helped the company raise more than $400 million in private and public equity. Prior to joining Gensia, Mr. Burgess held positions at Castle & Cooke, Inc. and Smith Barney, Harris Upham and Company. Mr. Burgess received his BA in Economics from Stanford University and an MBA from Harvard Business School. Mr. Burgess is a member of the Board of Directors of Santarus, Inc. and Metabasis Therapeutics, Inc.